CWA
ALNY icon

Clarus Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Clarus Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-190
Closed -$14K – 164
2019
Q2 		$14K Hold
190
– – 0.01% 401
2019
Q1 		$18K Hold
190
– – 0.01% 430
2018
Q4 		$14K Buy
190
+95
+100% +$7.31K 0.02% 456
2018
Q3 		$8K Buy
+95
New +$9.56K 0.01% 563

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Clarus Wealth Advisors's ALNY Position: Q3 2019 in Review

Clarus Wealth Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2019, closing a stake of 190 shares — an estimated $14K sold.

Clarus Wealth Advisors first reported a position in ALNY in Q3 2018 and held it in 4 quarters. The position peaked at $18K in Q1 2019. 281 funds tracked by Wall St. Rank hold ALNY as of Q3 2019.

  • Clarus Wealth Advisors reported no remaining Alnylam Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Clarus Wealth Advisors sold 190 Alnylam Pharmaceuticals shares in Q3 2019, an estimated $14K.
  • Clarus Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2018 and held it in 4 quarters.
  • Clarus Wealth Advisors's Alnylam Pharmaceuticals position peaked at $18K in Q1 2019.
  • 281 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2019.

Based on Clarus Wealth Advisors's 13F filing for Q3 2019, filed 11 Oct 2019.